Immix Biopharma Inc faces significant financial challenges, including a negative P/E ratio, but its innovative approach to treating oncology and inflammatory bowel diseases remains promising.

Immix Biopharma Inc. has announced groundbreaking results for its NXC-201 therapy in treating AL Amyloidosis, with a 70% complete response rate in a Phase 1/2 clinical trial, positioning it as a potential best-in-class treatment.

Immix Biopharma Inc. has made significant progress in developing a treatment for relapsed/refractory AL Amyloidosis, with positive trial results and FDA RMAT designation positioning the company as a leader in the field.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company making steady progress in developing innovative, tissue-specific therapeutics for oncology and inflammation.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company making strides in oncology and inflammation therapies, with a focus on tissue-specific treatments for conditions like ulcerative colitis and Crohn’s disease.